

Specificity of murine delayed-type hypersensitivity to conjugates of large or small haptens on protein carriers bearing lipid groups

H. SNIPPE, LYNNE JOHANNESSEN, J. K. INMAN & B. MERCHANT *Division of Blood and Blood Products, Bureau of Biologics, Food and Drug Administration, and Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, Maryland, U.S.A.*

Received 25 August 1977; accepted for publication 15 September 1977

Summary. Delayed-type hypersensitivity (DH) in the mouse was provoked with different hapten-carrier complexes mixed with the cationic, surface-active lipid, dimethyl dioctadecyl ammonium bromide (DDA). DH was measured as footpad swelling.

Conjugates of bovine serum albumin (BSA) with the small haptens dinitrophenyl (DNP), 'arsonate' (ARS) and 'sulphonate' (SULPH) served to generate strong DH reactions towards the homologous antigen. Insertion of a tripeptide spacer between the hapten and carrier resulted in lower DH reactivity. Optimal dosages and optimal time intervals between sensitization and DH elicitation were determined for the enlarged hapten-carrier complexes. Cyclophosphamide (CY) treatment, before priming with complexes mixed with DDA, caused a 5-6 day delay in the expression of DH but failed to evoke enhanced DH for any of the antigens tested.

A broad array of cross reactions between small and enlarged hapten-carrier complexes showed a relative lack of specificity in these DH responses. The results are compared with others reported in the literature and are explained mainly by the effects of electrostatically bound lipid groups of DDA in the sensitizing conjugates.

Correspondence: Dr H. Snippe, Department of Immunology, Laboratory for Microbiology, Catharijnesingel 59, Utrecht, The Netherlands.

INTRODUCTION

Immunization of guinea-pigs with the hapten 2,4-dinitrophenyl (DNP) coupled directly to mycobacteria generated T lymphocytes responsive to DNP on a wide variety of carriers (Janeway, Cohen, Ben Sasson & Paul, 1975). These results contrast with most T-cell responses to hapten-carrier conjugates which are specific for carrier or for specific conjugate determinants, but not for the same hapten on heterologous carriers (Paul, 1970). It was further demonstrated (Janeway, Maurer, Daily & Inman, 1976) that hapten-specific T cells precisely discriminate the hapten used for priming from other haptens. They also showed that insertion of a tripeptide spacer between the hapten and carrier interfered with recognition of the hapten. This suggested that the carrier amino acids make essential contributions to the determinants or epitopes recognized by T cells.

The capacity of hapten coupled mycobacteria to activate T cells to 'conjugate-specific' determinants was also found with DNP-BSA when lipid groups were covalently attached to the BSA (Daily & Hunter, 1974). They also used the cationic, surface-active lipid, dimethyl dioctadecyl ammonium bromide (DDA) to introduce lipid groups via electrostatic bonds with the hapten-carrier complexes. Immunization of guinea-pigs (Daily &

Hunter, 1974) or mice (Snippe, Belder & Willers, 1977) with DNP-carrier complexes mixed with DDA produced hapten-specific delayed type hypersensitivity (DH). The purpose of the present study was to investigate the specificity of DH in mice immunized with complexes of different small or enlarged haptens on carriers bearing electrostatically-bound lipid groups of DDA.

MATERIALS AND METHODS

Animals and immunization

Inbred female BALB/c mice were obtained from the Animal Production Section, NIH, and were used at an age of about 10 weeks. For each experiment, groups containing six to eight mice were used. Different amounts of hapten-protein conjugate, dissolved in 0.1 ml saline and homogenized with 0.1 ml (100 µg) of DDA (Eastman Kodak, New York), were injected intracutaneously (i.c.) in the abdomen, at two separate sites.

Antigens

The haptens employed in this study are listed in Table 1. Large haptens have been given *single* capital letter designations. The abbreviations DNP, ARS and SULPH have been employed for the small haptens. The procedures for synthesis of the special tripeptide-enlarged haptens were those reported by Inman, Merchant & Tacey (1973). DNP-BSA coupling was carried out and analysed according to the method of Eisen, Carsten & Belman (1954). ARS-

BSA and SULPH-BSA were prepared according to the method of Tabachnick & Sobotka (1960). Coupling of enlarged haptens to protein was performed as described by Inman, Merchant, Clafin & Tacey (1973). Haptenated Ficoll antigens were prepared as described by Inman (1975).

Assay for delayed-type hypersensitivity (DH)

The DH reactions were determined by measuring the increase in footpad thickness (footpad swelling test) as described by Kerckhaert, van den Berg & Willers (1974). In all the experiments the test dose of 10 µg of antigen suspended in 0.05 ml saline was injected into the left hind footpad. A footpad swelling of 0.25 mm is regarded as positive. The results are expressed as the increment of the footpad thickness in 0.1 mm units ± the standard error of the mean (SEM) for six to eight mice.

Cyclophosphamide treatment

Cyclophosphamide (CY) was obtained from Koch-Light Laboratories (Colnbrook, Bucks., U.K.). The mice received an intraperitoneal (i.p.) injection of CY (300 mg/kg) in 0.5 ml of saline, 8 h before i.c. immunization with antigen.

RESULTS

Optimal dose for DH on enlarged hapten-carrier complexes

In previous experiments Snippe, Belder & Willers (1977) showed that the maximal footpad swelling

Table 1. Letter symbols and chemical designation* for haptens employed in this study

Small haptens
DNP = N-2,4-dinitrophenyl
ARS = p-azobenzene arsonate
SULF = p-azobenzene sulphonate
Large haptens
<i>TGG series</i>
A = 3-(p-arsonophenylazo)-N-acetyl-L-tyrosylglycylglycine
M = 3-(p-trimethylaminophenylazo)-N-acetyl-L-tyrosylglycylglycine
θ = 3-(phenylazo)-N-acetyl-L-tyrosylglycylglycine
V = 3-(p-carboxyphenylazo)-N-acetyl-L-tyrosylglycylglycine
G = unsubstituted N-acetyl-L-tyrosylglycylglycine
<i>AGG series</i>
K = N-(2,4,6-trinitrophenyl)-β-alanyl-glycylglycine
N = N-(4-hydroxy-3-iodo-5-nitrophenylacetyl)-β-alanyl-glycylglycine

* Structural formulae for most of the large haptens are presented in the reference of Inman, Merchant & Tacey (1973).

Table 2. Dose effect in delayed-type hypersensitivity

Antigen	Sensitization (μg)	Footpad swelling in 0.1 mm \pm SEM		
		Elicitation (μg)		
		3	10	30
K ₂₃ -BSA	3	10.5 \pm 1.1	10.3 \pm 0.3	6.0 \pm 1.1
	10	11.7 \pm 1.2	12.6 \pm 1.5	11.3 \pm 0.6
	30	6.4 \pm 0.8	9.3 \pm 1.7	10.2 \pm 1.2
	100	8.6 \pm 1.3	6.3 \pm 1.1	10.4 \pm 1.7
J ₃₀ -BSA	3	6.5 \pm 1.3	5.3 \pm 0.9	
	10	6.2 \pm 1.5	8.8 \pm 1.6	
	30	5.1 \pm 1.0	7.8 \pm 0.5	
	100	6.6 \pm 2.2	7.5 \pm 1.2	
A ₂₂ -BSA	3	4.3 \pm 0.6	5.0 \pm 1.6	7.7 \pm 1.3
	10	4.7 \pm 1.5	12.8 \pm 1.8	10.8 \pm 1.2
	30	4.7 \pm 1.2	9.5 \pm 1.1	10.0 \pm 2.0
	100	8.5 \pm 1.5	8.7 \pm 1.9	8.0 \pm 2.2

Groups of five mice were immunized with 3, 10, 30 or 100 μg antigen in 100 μg DDA and 5 days later elicited with 3, 10 or 30 μg of the homologous antigen.

after priming with antigen in DDA was measured at days 5 and 6. With this time interval the optimal dose was determined for sensitization and elicitation of DH with the enlarged hapten-carrier complexes. Groups of five mice were immunized with 3, 10, 30 or 100 μg of K₂₃-BSA, J₃₀-BSA or A₂₂-BSA in 100 μg DDA and 5 days later were challenged with 3, 10 or 30 μg of the homologous antigen (Table 2). Optimal responses were obtained with 10 μg used both for priming and eliciting injections. Unexpectedly, the response to J₃₀-BSA was less than the response to K₂₃-BSA or to A₂₂-BSA. This phenomenon was not dose dependent (unpublished data).

DH on small and enlarged hapten-carrier complexes

As shown earlier, DH was influenced by the hapten-carrier ratio in DNP-BSA complexes (Snippe, Willers, Grave & Kamp, 1975; Snippe *et al.*, 1977). To investigate the role of the hapten, groups of mice were immunized with 10 μg of a small or an enlarged hapten-carrier complex in DDA and, 5 days later, responses were elicited with 10 μg of the homologous antigen. A strong DH response was observed with the small hapten-carrier complexes DNP₃₁-BSA, ARS₇-BSA, SULPH₁₆-BSA and ARS₇-OVA (Table 3). The enlarged hapten complexes K₂₃-BSA, A₂₂-BSA and N₄₃-BSA were slightly less

Table 3. Delayed-type hypersensitivity reactions to hapten-carrier complexes

Footpad swelling in 0.1 mm \pm SEM			
Small haptens		Enlarged haptens	
DNP ₅ -BSA	3.0 \pm 0.6	K ₂₃ -BSA	13.7 \pm 1.0
DNP ₃₁ -BSA	18.4 \pm 1.2	J ₃₀ -BSA	7.8 \pm 0.4
ARS ₇ -BSA	14.2 \pm 1.2	A ₂₂ -BSA	11.8 \pm 1.3
SULF ₁₆ -BSA	13.6 \pm 0.7	N ₄₃ -BSA	11.7 \pm 0.9
ARS ₇ -OVA	14.4 \pm 2.0	θ_{41} -BSA	8.4 \pm 0.5
		G ₂₅ -BSA	2.3 \pm 0.5
		M ₁₆ -BSA	1.8 \pm 0.3
		θ_9 -HGG	6.2 \pm 0.4

Groups of mice (five to seventeen per group) were immunized *i.c.* with 10 μg of antigen in 100 μg of DDA and 5 days later responses were elicited with 10 μg of homologous antigen.

reactive, while J₃₀-BSA, θ_{41} -BSA and θ_9 -HGG gave only moderate reactions. The small hapten complex DNP₅-BSA and the enlarged hapten complexes G₂₅-BSA and M₁₆-BSA gave no significant DH. Neither the injection of the thymus independent antigens J₅₉-Ficoll and J₄₀-Ficoll alone (at various doses) with DDA nor the simultaneous injection of these thymus independent antigens and BSA resulted in DH (data not given).




Figure 1. The effect of CY treatment before priming on DH. Groups of eight mice were immunized i.c. with 10 μ g of K₂₃-BSA in DDA 8 h after i.p. injection of saline (●) or CY (○). Challenge with 10 μ g of K₂₃-BSA was performed by footpad injection at varying time intervals thereafter. The increase in footpad thickness was measured 24 h after challenge. Vertical bars indicate SEM.

Interval between priming and eliciting injections with K₂₃-BSA

In a previous paper (Snippe, Belder & Willers, 1977) the effect of the interval between priming and eliciting injections on DH to DNP₂₈-BSA was studied with and without pretreatment with CY. The present study was extended to the enlarged hapten-carrier complex, K₂₃-BSA. At different intervals after immunization with 10 μ g of K₂₃-BSA, groups of six mice were elicited with 10 μ g of K₂₃-BSA. In control mice DH was present at day 4, reached a maximum at day 5 and decreased slowly thereafter (Fig. 1). To investigate the effect of CY, groups of mice received an i.p. injection of CY (300 mg/kg) and were sensitized 8 h later with 10 μ g of K₂₃-BSA. The DH response was markedly impaired until about 7 days after immunization but was fully expressed between days 9 and 12 (Fig. 1). No difference in the maximum height of the response (day 11 vs day 5) was observed.

The effect of CY treatment on DH to different hapten-carrier complexes

The influence of CY treatment on DH was further analysed for other hapten-carrier complexes. Groups of mice received CY 8 h before the antigen was given. DH responses were elicited with the homologous antigen at day 11. Control groups received




Figure 2. Homologous DH reactions with different hapten-carrier complexes. Groups of eight mice were immunized with 10 μ g of antigen in DDA 8 h after i.p. injection of saline (□, □) or CY (■, ■). DH responses were elicited in these mice by left footpad injection of the same dose of the homologous antigen at day 5 (□, □) or day 11 (□, ■). The increase in footpad thickness was measured 24 h later. Vertical bars indicate SEM.

no CY and their responses were elicited at day 5 or day 11. Fig. 2 shows that in all instances the response of the control groups is lower at day 11 than at day 5. In most instances, however, CY treatment resulted in a maximal response at day 11 which was closely comparable to the response of the controls at day 5. This delay and recovery of amplitude after CY treatment was not obtained to the same degree with A₂₂-BSA or with θ ₄₁-BSA.

Cross reactions between small haptens

To determine the haptenic specificity of DH in mice, cross reactions between small haptens were studied. Groups of mice immunized with 10 μ g of DNP₅-BSA, DNP₃₁-BSA, ARS₇-BSA and SULPH₁₆-BSA were challenged with the homologous or a heterologous antigen 5 days later (Table 4). Mice immunized with DNP₅-BSA were responsive only to DNP₃₁-BSA. Mice sensitized with DNP₃₁-BSA showed a strong response to the homologous antigen but also showed an appreciable response to SULPH₁₆-BSA and to ARS₇-BSA. Priming with ARS₇-BSA or SULPH₁₆-BSA resulted in cross reactions to SULPH₁₆-BSA and to ARS₇-BSA, respectively.

Table 4. Cross reactions in delayed-type hypersensitivity between small haptens on an identical carrier

Sensitization	Footpad swelling in 0.1 mm \pm SEM			
	Elicitation			
	DNP ₅ -BSA	DNP ₃₁ -BSA	ARS ₇ -BSA	SULF ₁₆ -BSA
DNP ₅ -BSA	2.3 \pm 0.4	9.1 \pm 0.6*	3.5 \pm 0.4†	2.7 \pm 0.6‡
DNP ₃₁ -BSA	4.9 \pm 0.8*	17.6 \pm 0.9	7.9 \pm 1.1*	10.7 \pm 1.4*
ARS ₇ -BSA	1.9 \pm 0.6*	3.6 \pm 0.7*	13.2 \pm 0.8	13.4 \pm 0.9‡
SULF ₁₆ -BSA	2.9 \pm 0.5*	4.9 \pm 0.6*	12.2 \pm 0.5*	14.9 \pm 0.8

Groups of mice were immunized i.c. with 10 μ g of antigen in 100 μ g DDA, and 5 days later their DH responses were elicited with 10 μ g of a test antigen. The following symbols denote *P* values obtained by comparing the effectiveness of the homologous antigen versus that of other antigens in eliciting DH among groups of mice, all of which received the same sensitizing antigen. * *P* < 0.005; † *P* < 0.025; ‡ *P* value not significant.

Cross reactions between enlarged haptens

Enlarged haptens generate multiple diverse populations of antibody forming cells (Merchant & Inman, 1977), so it is possible that this effect might also be reflected in DH responses to enlarged haptens. Groups of mice immunized with 10 μ g of K₂₃-BSA, J₃₀-BSA, A₂₂-BSA or N₄₃-BSA received the standard eliciting injections on day 5. Mice sensitized with A₂₂-BSA or N₄₃-BSA showed a strong response to the homologous antigen and weaker reactions to most other antigens (Table 5). On the other hand, mice immunized with K₂₃-BSA showed a strong DH reaction to the homologous antigen and also to a number of other antigens including the non-related antigens A₂₂-BSA and N₄₃-BSA. Similar

results were obtained after sensitization with J₃₀-BSA. Although the optimal DH response was generally lower, the cross reactions tended to occur with the same antigens as for K₂₃-BSA. When used for sensitization, the enlarged haptens A and N stimulated DH which was far more specific than that seen for J and K.

Cross reactions between small and enlarged haptens

In order to evaluate the capacity for haptenic recognition in the receptors on those cells expressing DH, the influence of a spacer between hapten and carrier was studied. Groups of mice were immunized with DNP₃₁-BSA, ARS₇-BSA or SULPH₁₆-BSA and their

Table 5. Cross-reactions in delayed-type hypersensitivity between large haptens on an identical carrier

Sensitization	Footpad swelling in 0.1 mm \pm SEM								
	Elicitation								
BSA	K ₂₃ -BSA	J ₃₀ -BSA	A ₂₂ -BSA	N ₄₃ -BSA	θ ₄₁ -BSA	G ₂₅ -BSA	M ₁₆ -BSA	V ₆ -BSA	
K ₂₃ -BSA	1.5 \pm 0.3*	14.2 \pm 0.4	12.0 \pm 1.1†	13.6 \pm 1.5‡	12.9 \pm 0.7‡	5.6 \pm 0.5*	3.8 \pm 0.4*	2.7 \pm 0.3*	1.9 \pm 0.4*
J ₃₀ -BSA	0.8 \pm 0.2*	7.5 \pm 0.8‡	8.6 \pm 0.5	5.9 \pm 0.7‡	8.7 \pm 1.5‡	3.4 \pm 1.0*	2.9 \pm 0.3*	2.8 \pm 0.6*	n.t.
A ₂₂ -BSA	1.3 \pm 0.1*	4.8 \pm 0.7*	4.2 \pm 0.6*	12.1 \pm 0.6	4.3 \pm 1.0*	4.8 \pm 1.0*	3.8 \pm 0.7*	3.1 \pm 0.6*	2.4 \pm 0.5*
N ₄₃ -BSA	1.2 \pm 0.3*	5.8 \pm 1.2*	5.7 \pm 0.3*	7.6 \pm 0.6*	13.2 \pm 1.0	5.2 \pm 0.9*	n.t.	n.t.	1.5 \pm 0.2*

n.t. = not tested. Sensitization and elicitation procedures were the same as those outlined in Table 4. Number of mice per group 10–25. The following symbols denote *P* values obtained by comparing the effectiveness of the homologous antigen versus that of other antigens in eliciting DH among groups of mice, all of which received the same sensitizing antigen. * *P* < 0.005; † *P* < 0.025; ‡ *P* value not significant.

Table 6. Cross reactions in delayed-type hypersensitivity between small and large haptens on an identical carrier

Sensitization	Footpad swelling in 0.1 mm \pm SEM Elicitation			
	K ₂₃ -BSA	A ₂₂ -BSA	N ₄₃ -BSA	θ_{41} -BSA
DNP ₃₁ -BSA	6.1 \pm 1.2†	5.2 \pm 1.7	5.3 \pm 1.5	4.7 \pm 0.9
ARS ₇ -BSA	3.4 \pm 0.9	3.5 \pm 0.8§	3.9 \pm 0.8	2.9 \pm 1.1
SULF ₁₆ -BSA	3.4 \pm 0.9	2.4 \pm 0.6	2.8 \pm 0.8	n.t.

Sensitization	Elicitation		
	DNP ₃₁ -BSA	ARS ₇ -BSA	SULPH ₁₆ -BSA
K ₂₃ -BSA	12.5 \pm 0.9†	11.8 \pm 1.2	13.9 \pm 1.3
J ₃₀ -BSA	8.7 \pm 0.9	8.0 \pm 1.2	9.0 \pm 1.8
A ₂₂ -BSA	4.0 \pm 0.8*	7.7 \pm 1.0*§	5.7 \pm 1.4
N ₄₃ -BSA	4.2 \pm 0.9†	7.9 \pm 0.7†	6.1 \pm 0.8

n.t. = not tested. Sensitization and elicitation procedures were the same as those outlined in Table 4. Number of mice per group: 10–20. Elicitation of groups receiving the same sensitizing antigen and sharing a common symbol * or † differ significantly from each other. $P < 0.005$, all others were not significant. In comparisons between corresponding experiments, the groups marked ‡ and § differ significantly: P value < 0.005 .

DH responses were elicited 5 days later with enlarged haptens on BSA. Mice primed with DNP₃₁-BSA showed a weak response to all complexes tested (Table 6). ARS₇-BSA and SULPH₁₆-BSA sensitized mice for only marginal or insignificant responses. Thus, conjugates containing large haptens were never able to elicit strong DH responses in mice sensitized with the corresponding small haptens (compare Tables 4 and 6).

Sensitization with enlarged haptens resulted in strong cross reactions to the small haptens DNP, ARS and SULPH if the mice were primed with K₂₃-BSA or J₃₀-BSA, and weaker cross reactions if they were primed with A₂₂-BSA or N₄₃-BSA.

DISCUSSION

In a previous study (Snippe *et al.*, 1977) it was demonstrated that immunization with DNP-carrier complexes in DDA resulted in hapten specific DH, provided the epitope density was sufficiently high. In contrast with the response following the use of Freund's complete adjuvant (FCA) no carrier

specific DH could be obtained when DDA was used as an adjuvant. Conceivably, the native carrier determinants have been effectively covered by the numerous bulky groups of bound DDA.

Extension of the use of DDA to the response to complexes with different haptens revealed DH towards all complexes with small haptens, provided the epitope density was high enough. Insertion of a spacer between hapten and carrier resulted in considerably lower (DNP or J) or slightly lower (ARS or A) DH values. No significant response was found to the non-haptenated carrier-spacer complex (G₂₅-BSA). This is in line with the results of Stashenko & Schlossman (1977) who used *in vitro* stimulation tests which showed that non-haptenated oligolysine alone was considerably less stimulatory than DNP substituted peptides. Their results demonstrated that T cells recognize a conjugate determinant composed of both the oligolysine and DNP moieties.

Treatment of mice with CY before sensitization with SRBC results in a delay in the onset but finally in an enhanced DH response (Kerckhaert, van den Berg & Willers, 1974). CY treatment preceding

immunization with hapten-carrier complexes emulsified in DDA resulted in DH responses very similar to or of only slightly lower magnitude than those obtained without CY. These results are in accordance with earlier findings in which CY pretreatment enhanced DH responses following immunization in FCA, but produced nearly full scale DH after immunization in DDA (Snippe *et al.*, 1977). These results suggest that DDA treatment favours expression of DH responses at or near optimal physiological levels.

Studies on cross reactions revealed a notable lack of specificity in many instances, for example as seen after immunization with DNP₃₁-BSA. Both small and enlarged hapten complexes elicited homologous DH responses. Sensitization with ARS₇-BSA caused cross sensitivity to SULPH₁₆-BSA, but sensitization with SULPH₁₆-BSA primed mice for significant cross reactions against ARS₇-BSA and for marginal cross reactions against DNP₃₁-BSA. Immunization with the DNP and TNP containing enlarged hapten complexes (K₂₃-BSA and J₃₀-BSA) resulted again in extensive cross reactions with enlarged and small hapten complexes. Sensitization with N₄₃-BSA, led to rather strong cross reactions with A₂₂-BSA a complex bearing a non-related hapten. Following immunization with A₂₂-BSA, only weak reactions on some of the other enlarged complexes (Table 5) and stronger reactions on ARS₇-BSA and SULPH₁₆-BSA were encountered (Table 6). A₂₂-BSA was the only sensitizing complex used in these experiments which had the N-acetyl-L-tyrosylglycylglycine spacer. More experiments will be necessary to draw conclusions regarding the influence of the type of spacer used on the final expression of specificity. Nonetheless, the 'immunodominant' distal terminus of the enlarged haptenic structures often failed to manifest the type of dominance in DH that is often expected for humoral immune responses.

Our results share notable similarities with the *in vitro* stimulation tests of Janeway *et al.* (1976a). They showed that lymphocytes of strain 2 guinea-pigs primed *in vivo* with conjugated mycobacteria could be stimulated *in vitro* with DNP linked to a great variety of carriers. They explained the lesser specificity of the lipid-containing conjugate used for priming on the basis of its ability to bind by non-specific hydrophobic forces to T-cell membrane lipid, thus stabilizing the weak interaction between the DNP group and any receptor even partially

specific for it (Janeway & Paul, 1976b). The broad array of cross reactions in DH following immunization with complexes containing the electrostatically bound lipid groups of DDA seems to support this hypothesis.

It seems likely that the receptors which determine T-cell specificity differ substantially from those which determine B cell specificity. Moreover, any T-cell propensity for cross-reactivity or alloreactivity (Merchant & Inman, 1977) was probably further amplified in the present studies by associated lipid binding.

ACKNOWLEDGMENT

Dr Snippe was sponsored by the Foreign Visitor Exchange Program of the Food and Drug Administration. Grant no. G-5-26.

REFERENCES

- DAILEY M.O. & HUNTER R. (1974) The role of lipid in the induction of hapten-specific delayed hypersensitivity and contact sensitivity. *J. Immunol.* **112**, 1526.
- EISEN H.N., CARSTEN S. & BELMAN S. (1954) Studies of hypersensitivity to low molecular weight substances. III. The 2,4-dinitrophenyl group as a determinant in the precipitin reaction. *J. Immunol.* **73**, 296.
- INMAN J.K. (1975) Thymus independent antigens: the preparation of hapten-Ficoll conjugates. *J. Immunol.* **114**, 704.
- INMAN J.K., MERCHANT B. & TACEY S.E. (1973) Synthesis of large haptenic compounds having a common functional group that permits covalent linkage to proteins, cell surfaces and adsorbents. *Immunochemistry*, **10**, 153.
- INMAN J.K., MERCHANT B., CLAFLIN L. & TACEY S.E. (1973) Coupling of large haptens to proteins and cell surfaces: preparation of stable, optimally sensitized erythrocytes for hapten-specific, hemolytic plaque assays. *Immunochemistry*, **10**, 165.
- JANEWAY C.A., COHEN B.E., BEN-SASSON S.Z. & PAUL W.E. (1975) The specificity of cellular immune responses in guinea pigs. I. T cells specific for 2,4-dinitrophenyl-0-tyrosyl residues. *J. exp. Med.* **141**, 42.
- JANEWAY C.A., MAURER P.H., DAILEY M.O. & INMAN J.K. (1976a) The specificity of cellular immune responses in guinea-pigs. II. The structure of antigenic determinants leading to T-lymphocyte stimulation. *J. exp. Med.* **144**, 1621.
- JANEWAY C.A. & PAUL W.E. (1976b) The specificity of cellular immune responses in guinea-pigs. III. The precision of antigen recognition by T lymphocytes. *J. exp. Med.* **144**, 1641.
- KERCKHAERT J.A.M., VAN DEN BERG G.J. & WILLERS J.M.N. (1974) Influence of cyclophosphamide on the

- delayed hypersensitivity of the mouse. *Ann. Immunol.* **1250**, 415.
- MERCHANT B. & INMAN J.K. (1977) Hapten-specific hemolytic plaque assay usually fail to detect most of the diversity in the anti-hapten response. *J. exp. Med.* **145**, 372.
- PAUL W.E. (1970) Functional specificity of antigen binding receptors of lymphocytes. *Transplant. Rev.* **5**, 130.
- SNIPPE H., WILLERS P.J., GRAVEN W.G. & KAMP E. (1975) Delayed hypersensitivity in the mouse induced by hapten-carrier complexes. *Immunology*, **28**, 897.
- SNIPPE H., BELDER M. & WILLERS J.M.N. (1977) Dimethyl dioctadecyl ammonium bromide as adjuvant for delayed hypersensitivity in mice. *Immunology*, **33**, 931.
- STASHENKO P.P. & SCHLOSSMAN S.F. (1977) Antigen recognition: the specificity of an isolated T lymphocyte population. *J. Immunol.* **118**, 544.
- TABACKNICK M. & SOBOTKA H. (1960) Azoproteins. II. A spectrophotometric study of the coupling of diazotized arsanilic acid with proteins. *J. biol. Chem.* **4**, 235.